Brainomix joined up with Boehringer Ingelheim this week in Manchester to attend the NHS Expo, the largest NHS-led event of the year. The event was focused primarily on the NHS Long Term Plan, and was attended by a number of key stakeholders, including Simon Stevens, Chief Executive of NHS England.
Brainomix was featured within Boehringer Ingelheim’s Clinical Improvement Zone alongside clinical data experts PRIMIS. “We are proud to be standing alongside our partners PRIMIS and Brainomix at Expo to show how working together can help deliver the Long Term Plan. We fundamentally believe that sharing expertise and collaborating openly has the potential to drive system transformation and ultimately benefit patients throughout the UK,” noted Uday Bose, Country Managing Director and Head of Human Pharmaceuticals at Boehringer Ingelheim.
During a session Wednesday morning entitled Using AI Software to Transform Stroke Care Pathways and Create System Change in the NHS, Dr George Harston (Chief Medical & Innovation Officer at Brainomix, and Consultant Physician in Acute, Geriatric & Stroke Medicine, Oxford University Hospitals NHS Foundation Trust) presented an overview of Brainomix’s e-Stroke Suite platform. “The NHS Expo was a great opportunity for us to showcase our technology to a wide range of health care providers and administrators, all of whom were highly interested in AI platforms such as our e-Stroke Suite, which has been shown to transform stroke care across networks,” noted Dr George Harston. Dr David Cohen (Consultant Physician, Northwick Park Hospital, London) also presented during the session, discussing his experience with Brainomix’s e-ASPECTS software, and how it has benefitted his hospital’s stroke practice. Northwick Park were one of the first adopters of Brainomix technology in the UK and continue to be a leading provider of stroke care, with one of the fastest door-to-needle times in the country.
The partnership between Brainomix and Boehringer Ingelheim has enabled both companies to present a wider array of solutions for stroke providers in the UK, while also addressing components of the NHS Long Term Plan. “Boehringer Ingelheim have been a valued partner of Brainomix for many years. We have been working hand-in-hand with Boehringer Ingelheim to improve stroke care throughout Europe and we see a great opportunity through our partnership to improve how stroke patients are treated in the NHS,” commented Dr Michalis Papadakis, CEO of Brainomix. Brainomix’s e-Stroke Suite is the most comprehensive imaging solution, empowering clinicians across all stages of the stroke patient pathway and supporting the thrombectomy decision-making process, from non-contrast CT interpretation, to collateral assessments and LVO detection, to more advanced perfusion-based assessments.